Atossa Therapeutics (ATOS) Income from Continuing Operations (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Income from Continuing Operations of 9589000.0 for Q1 2026, down 42.74% year-over-year from 16745230.57 in Q1 2025, and up 12.33% quarter-over-quarter from 10937000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Income from Continuing Operations for 16 consecutive years, with 9589000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 42.74% year-over-year to 9589000.0; the TTM figure through Mar 2026 stood at 37641000.0 (down 79.35% YoY), while the FY2025 annual figure was 34770000.0, down 72.57% from the prior year.
- Income from Continuing Operations climbed to 9589000.0 in Q1 2026 per ATOS's latest filing, from 10937000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 991000.0 in Q4 2024 and bottomed at 10937000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 7150647.06 across 5 years, with a median of 7230000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 1383.37% — and 2024, when it jumped 87.22%.
- Atossa Therapeutics' Income from Continuing Operations stood at 7491000.0 in 2022, then decreased by 3.51% to 7754000.0 in 2023, then surged by 87.22% to 991000.0 in 2024, then tumbled by 1003.63% to 10937000.0 in 2025, then gained by 12.33% to 9589000.0 in 2026.
- Business Quant data shows ATOS's Income from Continuing Operations at 9589000.0 in Q1 2026, 10937000.0 in Q4 2025, and 8692000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -8.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.49 Mn |
| Mar 31, 2026 | -9.59 Mn |
| Dec 31, 2025 | -10.94 Mn |
| Sep 30, 2025 | -8.69 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Mar 31, 2025 | -6.72 Mn |
| Dec 31, 2024 | -991,000.00 |
| Sep 30, 2024 | -7.23 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Dec 31, 2023 | -7.75 Mn |
| Sep 30, 2023 | -6.23 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -6.28 Mn |
| Dec 31, 2022 | -7.49 Mn |
| Sep 30, 2022 | -8.01 Mn |
| Jun 30, 2022 | -6.67 Mn |
| Mar 31, 2022 | -4.79 Mn |
| Dec 31, 2021 | -505,000.00 |
| Sep 30, 2021 | -5.20 Mn |